Next Investors logo grey
  1. Home
  2. Asx Biotech

Asx Biotech

EMD up 37% on no news yesterday… MDMA Therapy for First Responders

Next Investors Mar 08, 2024

Yesterday, our biotech investment Emyria (ASX:EMD) was up 37% on no news.

The 8 Reasons we Invested in EMD

Next Investors Sep 05, 2023

In today's note we deep dive into the 8 reasons we Invested in Emyria (ASX:EMD). EMD is an integrated clinical drug development and care delivery company whose primary area of focus is on psychedelics such MDMA, psilocybin and more recently, ketamine for treatment of mental health disorders

eSense-Lab strikes JV to develop and a sell new range of terpene products

Finfeed Archived Jun 15, 2020

eSense-Lab Limited (ASX: ESE) has entered a JV with ANC Enterprises to provide specific terpenes uniquely developed for a range of skin care, hair care and hand sanitiser products. ANC will formulate and manufacture the resulting products containing ESE’s proprietary terpene mixes.

PharmAust shares soar following promising COVID-19 treatment results

Finfeed Archived Jun 04, 2020

PharmAust's (ASX:PAA) demonstrates both infectivity and replication of SARS-CoV-2 virus particles can be suppressed in cell cultures.

GTG developing a genetic test in the fight against COVID-19

Finfeed Archived May 22, 2020

Genetic Technologies (ASX: GTG | NASDAQ: GENE) is fast-tracking development of a genetic test that will determine if people are at a high risk of contracting COVID-19.

Join Our
Mailing List